<p>Indian pharmaceutical sector is now blooming again after plenty of ups and down in past few years handling plenty of regulatory challenges such as recast of FDI policy, patent protection, pricing policies of the US generic market, regulatory approvals, compulsory licensing, QC standards etc.</p><p>Implementation of the GST, less new products launching and high competition and cost really disturbed the sector. Currently, the government has launched a new price index for the pharmaceutical products, which became the benchmark for the determining prices of all the medicines which are sold in the country</p><blockquote><p>Implementation of the GST, less new products launching and high competition and cost really disturbed the sector. Currently, the government has launched a new price index for the pharmaceutical products, which became the benchmark for the determining prices of all the medicines which are sold in the country.</p></blockquote><p>On the other side the pharma companies are continuously investing in the R&amp;amp;D which has enabled them to be develop a basket of products for the markets across the world. In International markets, the pricing pressure on generic sold in the US has support the sector whereas Indian pharma industry is also preparing to enter the second largest pharmaceutical sector China.</p><p>Currently the clearance of the Sun pharma Halol plant, Gujarat has also boosted a lot and provided a big support to the pharmaceutical marker.</p>